CPHA Canvax
CPHA Canvax

"N. meningitidis serogroup B strain is the most prevalent form of invasive meningococcal disease in Canada. Although this infection is relatively rare, no other bacterial agent may kill as swiftly after bloodstream invasion as the meningococcus. With the availability of vaccines to protect against the different serogroups, it is important for clinicians to educate patients on the potential risks of meningococcal infection and the benefits of immunization. This program will review the clinical consequences of meningococcal type B infection, the different vaccine options and how it can be integrated into practice." - Meningococcal Type B – Protecting Against The Most Common Cause Of Invasive Meningococcal Disease (IMD) In Canada

This course is available until June 18, 2021 


Web link

Meningococcal Type B – Protecting Against the Most Common Cause of invasive meningococcal disease (IMD) in Canada

Related Resources

Bookmark

Implementation Tool

Link

Category

Program Planning and Delivery,Professional Development,Education and Training,Vaccine Preventable Diseases,Communicable Diseases,Meningococcal Disease Program Planning and Delivery
Professional Development
Education and Training
Vaccine Preventable Diseases
Communicable Diseases
Meningococcal Disease

0 Comments

Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.